[go: up one dir, main page]

ATE398107T1 - N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme - Google Patents

N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Info

Publication number
ATE398107T1
ATE398107T1 AT04736241T AT04736241T ATE398107T1 AT E398107 T1 ATE398107 T1 AT E398107T1 AT 04736241 T AT04736241 T AT 04736241T AT 04736241 T AT04736241 T AT 04736241T AT E398107 T1 ATE398107 T1 AT E398107T1
Authority
AT
Austria
Prior art keywords
reuppost
noradrenaline
serotonin
pyrrolidine
inhibitors
Prior art date
Application number
AT04736241T
Other languages
English (en)
Inventor
Paul Vincent Fish
Michael Jonathan Fray
Alan Stobie
Florian Wakenhut
Gavin WHITLOCK
Alan Daniel Brown
Mark David Andrews
Mark Lansdell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE398107T1 publication Critical patent/ATE398107T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04736241T 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme ATE398107T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
US49312603P 2003-08-06 2003-08-06

Publications (1)

Publication Number Publication Date
ATE398107T1 true ATE398107T1 (de) 2008-07-15

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04736241T ATE398107T1 (de) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Country Status (31)

Country Link
US (2) US7378436B2 (de)
EP (1) EP1638933B1 (de)
JP (1) JP4137159B2 (de)
KR (1) KR100803796B1 (de)
AP (1) AP2005003467A0 (de)
AR (1) AR044715A1 (de)
AT (1) ATE398107T1 (de)
AU (1) AU2004247487B2 (de)
BR (1) BRPI0411594A (de)
CA (1) CA2530159C (de)
CY (1) CY1110434T1 (de)
DE (1) DE602004014372D1 (de)
DK (1) DK1638933T3 (de)
EA (1) EA009881B1 (de)
EC (1) ECSP056232A (de)
ES (1) ES2305776T3 (de)
HR (2) HRP20080339T3 (de)
IL (1) IL172063A0 (de)
IS (1) IS8136A (de)
MA (1) MA27885A1 (de)
MX (1) MXPA05013960A (de)
NL (1) NL1026438C2 (de)
NZ (1) NZ544046A (de)
PA (1) PA8605301A1 (de)
PE (1) PE20050631A1 (de)
PL (1) PL1638933T3 (de)
PT (1) PT1638933E (de)
SI (1) SI1638933T1 (de)
TW (1) TW200505852A (de)
UY (1) UY28360A1 (de)
WO (1) WO2004110995A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1307194E (pt) 2000-07-31 2008-05-27 Nycomed Danmark Aps Composição à base de fentanil para administração nasal
KR100803796B1 (ko) * 2003-06-17 2008-02-14 화이자 인코포레이티드 세로토닌 및 노르아드레날린 재흡수 억제제로서의n-피롤리딘-3-일-아미드 유도체
BRPI0516602A (pt) 2004-10-18 2008-09-16 Lilly Co Eli composto, e, composição farmacêutica
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
JP2008523136A (ja) * 2004-12-14 2008-07-03 ファイザー・リミテッド セロトニンおよびノルアドレナリン再取り込み阻害剤としてのn−ピロリジン−3−イル−アミド誘導体
WO2006064336A2 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
TWI449692B (zh) 2005-05-13 2014-08-21 Otsuka Pharma Co Ltd 吡咯烷化合物(三)
RU2403250C2 (ru) 2005-06-02 2010-11-10 Ф.Хоффманн-Ля Рош Аг Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
WO2008093737A1 (ja) * 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. アミド誘導体
JP2010189275A (ja) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
RU2010129690A (ru) * 2007-12-19 2012-01-27 Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) Бициклические гетероциклические производные
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス, インコーポレーテッド 3−(フェノキシフェニルメチル)ピロリジン化合物
DK2358676T3 (da) * 2008-11-14 2013-01-14 Theravance Inc Krystallinsk form af en 4-[2-(2-fluorphenoxymethyl)phenyl]-piperidinforbindelse
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
EP2447264A4 (de) 2009-06-24 2012-12-12 Dainippon Sumitomo Pharma Co N-substituiertes zyklisches aminoderivat
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
ES2495366T3 (es) * 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
JP5705239B2 (ja) 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての1−(2−フェノキシメチルフェニル)ピペラジン化合物
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
US8471040B2 (en) 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (de)
US3963745A (en) * 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
JP2000500502A (ja) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
ATE345803T1 (de) 2000-03-03 2006-12-15 Eisai Co Ltd Neue methoden unter verwendung von cholinesteraseinhibitoren
IL151164A0 (en) * 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
WO2002024694A1 (en) 2000-09-22 2002-03-28 Smithkline Beecham, P.L.C. Pyrazolopyridines and pyrazolopyridazines as antidiabetics
CA2423315A1 (en) 2000-09-25 2002-03-28 Solange Meyer Substituted amino-aza-cycloalkanes useful against malaria
DE60237528D1 (de) 2001-09-14 2010-10-14 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
WO2003037865A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
MXPA04012893A (es) * 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
CA2511242C (en) 2002-12-20 2010-01-12 Anita Melikian Inhibitors of human tumor-expressed ccxckr2
KR100803796B1 (ko) * 2003-06-17 2008-02-14 화이자 인코포레이티드 세로토닌 및 노르아드레날린 재흡수 억제제로서의n-피롤리딘-3-일-아미드 유도체

Also Published As

Publication number Publication date
DE602004014372D1 (de) 2008-07-24
AR044715A1 (es) 2005-09-21
EA009881B1 (ru) 2008-04-28
KR100803796B1 (ko) 2008-02-14
MA27885A1 (fr) 2006-05-02
IL172063A0 (en) 2009-02-11
US20080306123A1 (en) 2008-12-11
ES2305776T3 (es) 2008-11-01
JP2006527758A (ja) 2006-12-07
PA8605301A1 (es) 2005-02-04
PE20050631A1 (es) 2005-09-14
CA2530159A1 (en) 2004-12-23
EA200501730A1 (ru) 2006-08-25
US7378436B2 (en) 2008-05-27
PL1638933T3 (pl) 2008-10-31
EP1638933A1 (de) 2006-03-29
KR20060036927A (ko) 2006-05-02
NL1026438A1 (nl) 2004-12-20
WO2004110995A1 (en) 2004-12-23
PT1638933E (pt) 2008-07-22
AU2004247487A1 (en) 2004-12-23
ECSP056232A (es) 2006-04-19
AU2004247487B2 (en) 2010-05-20
UY28360A1 (es) 2005-01-31
AP2005003467A0 (en) 2006-12-31
NZ544046A (en) 2009-08-28
US20050137229A1 (en) 2005-06-23
TW200505852A (en) 2005-02-16
WO2004110995A8 (en) 2005-04-21
DK1638933T3 (da) 2008-07-28
CA2530159C (en) 2010-02-02
HRP20080339T3 (en) 2008-08-31
CY1110434T1 (el) 2015-04-29
JP4137159B2 (ja) 2008-08-20
HRP20050993A2 (en) 2006-03-31
MXPA05013960A (es) 2006-02-24
BRPI0411594A (pt) 2006-08-29
NL1026438C2 (nl) 2005-09-20
IS8136A (is) 2005-11-21
EP1638933B1 (de) 2008-06-11
SI1638933T1 (sl) 2008-10-31

Similar Documents

Publication Publication Date Title
ATE398107T1 (de) N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DE502005011241D1 (de) Indazolderivate als inhibitoren der hormon-sensitiven lipase
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
ATE386730T1 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
DE60315516D1 (de) Pyridazinon-derivate als cdk2-hemmer
NO20045220L (no) Heterocykliske inhibitorer for kinaser
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
DE602005025363D1 (de) Substituierte amide als inhibitoren der beta-sekretase
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
NO20054880D0 (no) Azaspiroalkanderivater som inhibitorer av metallproeaser
EP1660436A4 (de) Cathepsininhibitoren
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase
ATE499096T1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
ATE430726T1 (de) N-acylamino-benzyletherderivate als selektive inhibitoren der monoaminoxidase b
DE60302152D1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
ATE353893T1 (de) Nicotinamid-derivate verwendbar als pde4 inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1638933

Country of ref document: EP

REN Ceased due to non-payment of the annual fee